Search

Displaying results 1981 - 1990 of 4335 in total
  1. Drug

    Ardeparin

    go.drugbank.com/drugs/DB00407
    ApprovedWithdrawn

    Normiflo was withdrawn from the US market in March 2000. … Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis.

  2. Drug

    Pheniprazine

    go.drugbank.com/drugs/DB09250
    ApprovedWithdrawn

    In addition, it was used for the treatment of other conditions, such as angina pectoris and schizophrenia. … Pheniprazine is an irreversible and nonselective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class that was used as an antidepressant in the 1960s.

  3. Drug

    Ezogabine

    go.drugbank.com/drugs/DB04953
    ApprovedWithdrawn

    It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures

  4. Drug

    Plerixafor

    go.drugbank.com/drugs/DB06809
    ApprovedInvestigational

    Plerixafor is a small-molecule inhibitor of C-X-C chemokine receptor type 4 (CXCR4) that acts as a hematopoietic stem cell mobilizer. … [A7118,L45678] As an inhibitor of CXCR4, plerixafor blocks the binding of its ligand, stromal cell-derived factor-1-alpha (SDF-1α).

  5. Drug

    Ferrous asparto glycinate

    go.drugbank.com/drugs/DB11169
    Approved

    It is available as a dietary supplement used in the treatment of iron deficiency and iron deficiency anemia.

  6. Drug

    Cabergoline

    go.drugbank.com/drugs/DB00248
    ApprovedInvestigational

    Cabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. Cabergoline possesses potent agonist activity on dopamine D2 receptors.

  7. Drug

    Selegiline

    go.drugbank.com/drugs/DB01037
    ApprovedInvestigationalVet approved

    A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may...

  8. Drug

    Selumetinib

    go.drugbank.com/drugs/DB11689
    ApprovedInvestigational

    Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important

  9. Drug

    Arbaclofen

    go.drugbank.com/drugs/DB08891
    Investigational

    It has also been investigated as a treatment for spasticity due to multiple sclerosis and spinal cord injury. … Arbaclofen was investigated as a treatment for gastroesophageal reflux disease (GERD); however, with disappointing results.

  10. Drug

    Pariglasgene brecaparvovec

    go.drugbank.com/drugs/DB16801
    Approved

    [L64050,L64051] It is administered as a single, one-time intravenous infusion.